天津武清龙济泌尿专科医院网站天津龙济包皮手术多少钱,天津市武清区龙济预约需要多长时间,天津龙济医院男科义诊,天津龙济网上男科,天津市龙济医院泌尿外天津市龙济,天津市武清区龙济医院男科看病要治疗费吗,天津市武清区龙济泌尿专科医院怎么走

WILMINGTON, Del. – President-elect Joe Biden is promising that his team is “going to get right to work” and is downplaying concerns that President Donald Trump’s refusal to acknowledge his victory could undermine national security.Trump has blocked his Democratic rival from receiving the intelligence briefings traditionally shared with incoming presidents, according to someone with knowledge of the situation but not authorized to disclose private conversations.Asked about the Republican resistance on Tuesday, Biden said it “does not change the dynamic at all in what we’re able to do.” He said additional intelligence briefings “would be useful,” but he doesn’t see anything slowing them down.“It would be nice to have it, but it’s not critical,” said Biden. “We’re just going to proceed the way we have. We’re going to do exactly what we’d be doing if he would have conceded and said we’ve won, which we have. And so, there’s nothing really changing.”Watch Biden and Sen. Kamala Harris speak below:Biden said he and his team are moving along in a “consistent manor,” putting together their administration and reviewing who they’d like to pick for cabinet positions.“Nothing’s going to stop that,” said Biden. “So, I’m confident that the fact that they’re not willing to acknowledge that we won at this point is not of much consequence in our planning and what we’re about to do between now and Jan. 20.”Biden also responded to comments from Senate Majority Leader Mitch McConnell, who said Monday that he supports Trump’s legal actions, despite there being little evidence of widespread voter fraud. Biden said he hasn’t gotten a chance to speak to McConnell yet, but he expects to relatively soon.“I think that the whole Republican Party has been put in a position, with a few notable exceptions, of being mildly intimidated by the sitting president,” said Biden. “But there’s only one president at a time. He’s president. We’re going to have the Electoral College, they’ll be making their judgment in December and it’ll be announced in early January, but in the meantime, I hope to get a chance to speak to Mitch.”When asked about the Trump administration blocking funding for the White House transition, Biden said he thinks his team can get things done without the money.“We can get through without the funding,” said Biden. “We don’t see anything that’s slowing us down, quite frankly.”So far, Biden said he’s been able to speak with six world leaders since he was projected to win the presidency on Saturday.“I’m letting them know that America is back. We’re going to be back in the game. It’s not America alone,” he said. “I’m confident that we’ll be able to put America back in a place of respect that it had before.”Biden said he believes Trump’s post-election behavior won’t help his legacy.“I know from my discussions with foreign leaders thus far, that they are hopeful that the United States’ democratic institutions are viewed as being strong and enduring,” said Biden. “I think at the end of the day, it’s all going to come to fruition on Jan. 20. And between now and then, my hope and expectation is that the American people do know and do understand that there has been a transition, even among Republicans.”When asked during his briefing what he would say to Trump if he were watching, Biden said “Mr. President, I look forward to speaking with you.” 3383

What's happening in the political world:Delta, United joins list of companies cutting ties with NRA-- Delta and United airlines have joined several large companies that pulled benefits offered to National Rifle Association members, following calls to boycott the organization following their response to the Parkland, Fla., school shooting.Delta tweeted that they have requested to be removed from the NRA's website: "Delta is reaching out to the NRA to let them know we will be ending their contract for discounted rates through our group travel program. We will be requesting that the NRA remove our information from their website.""United is notifying the NRA that we will no longer offer a discounted rate to their annual meeting and we are asking that the NRA remove our information from their website," United similarly tweeted Saturday.  Metlife, Symantec, and Enterprise are just some of the companies who announced they will cut ties with the NRA this week. None of the companies have given details about why or when they decided to cut ties, but the news comes as the hashtag #BoycottNRA has circulated widely on social media.Manafort indictment alleges secret payments to European politicians 1246

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

When two Stanford economists, Bob Wilson and Paul Milgrom, won the 2020 Nobel Prize in Economic Sciences, it was announced very early in the morning Pacific time. So early, that one of the men didn’t pick up their phone and was told about the award through his security camera.“Paul, it’s Bob Wilson. You’ve won the Nobel Prize, and they’re trying to reach you,” Wilson said to his co-recipient through the front door camera around 2 a.m. PT.Milgrom responds, “Wow, yeah, OK.” 484

Wildlife biologists with the Conservancy of Southwest Florida shared a shocking python find in Collier-Seminole State Forest on Thursday. An invasive Burmese python's eyes were a little bigger than its stomach when it decided to devour a white-tailed deer fawn. Officials say pythons have been known to kill and ingest large prey and this was a record breaking meal.  Officials stumbled upon the python with the massive prey inside. The biologists removed the python out of the wild into an open area and the python was stressed so it pushed the deer out of its mouth. In the photo below you can see the breathing tube and tongue of the python as it has its mouth wrapped around the deer. Biologists believe it is the largest python-to-prey ratio documented. The python was 31.5 pounds and the deer was 35 pounds; 111% of the python's mass. The findings will be published in the March 2018 issue of the Herpetological Review.“This observation is another important piece of evidence for the negative impact invasive Burmese pythons are having on native wildlife across the Greater Everglades Ecosystem” said Ian Bartoszek, Conservancy of Southwest Florida wildlife biologist. “Imagine the potential consequences to the state and federally protected Florida panther if Burmese pythons adversely affect the number of white-tailed deer, a panther’s primary prey.”Biologists are focused on the impact the python is having across the food chain. Since 2013, the Conservancy and its research partners have been conducting research to document the invasive Burmese python's biology and behavior in Collier County, including the tracking, removal and necropsy of captured pythons.Kelly Bazzle is the Digital Executive Producer at Scripps Station WFTS. Follow Kelly on Twitter.  1831